Gerd Geißlinger
← Back to Goethe University Frankfurt
Goethe University Frankfurt
Gerd Geißlinger works in Pain Mechanisms and Treatments, Inflammatory mediators and NSAID effects, Pharmacogenetics and Drug Metabolism, Sphingolipid Metabolism and Signaling, Ion Channels and Receptors. Recorded institutional associations include Goethe University Frankfurt, Fraunhofer Institute for Translational Medicine and Pharmacology, Fraunhofer-Gesellschaft.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
2001 · 747 citationsGTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence
2006 · 548 citationsCOX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib
2001 · 501 citationsChain length-specific properties of ceramides
2011 · 483 citationsCyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
2006 · 480 citationsZiconotide for treatment of severe chronic pain
2010 · 356 citationsMechanism-based treatment for chemotherapy-induced peripheral neuropathic pain
2014 · 344 citationsUp‐regulation of cyclooxygenase‐2 mRNA in the rat spinal cord following peripheral inflammation
1996 · 329 citationsPharmacokinetics of Opioids in Liver Disease
1999 · 306 citationsMicroarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer
2007 · 302 citationsCOX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites
2005 · 259 citationsGenetic Predictors of the Clinical Response to Opioid Analgesics
2004 · 256 citationsThe blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2
2022 · 229 citationsAnalgesic effects of morphine and morphine‐6‐glucuronide in a transcutaneous electrical pain model in healthy volunteers
2003 · 226 citationsCeramide synthases and ceramide levels are increased in breast cancer tissue
2009 · 225 citationsCapturing adenylyl cyclases as potential drug targets
2009 · 224 citationsThe polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine
2002 · 211 citationsLong chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth
2012 · 209 citationsThe IKK‐NF‐κB pathway: a source for novel molecular drug targets in pain therapy?
2008 · 209 citationsOpioids As Modulators of Cell Death and Survival—Unraveling Mechanisms and Revealing New Indications
2004 · 204 citationsFormation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators—What is the Evidence so far?
2022 · 196 citationsTHP-1 and human peripheral blood mononuclear cell-derived macrophages differ in their capacity to polarize in vitro
2017 · 192 citationsCeramides as Novel Disease Biomarkers
2018 · 188 citationsNo NO, no pain? The role of nitric oxide and cGMP in spinal pain processing
2009 · 187 citationsSAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
2016 · 177 citations
